What is the status of bosutinib/bosutinib generics?

Bosutinib/Bosutinib is a targeted therapy drug specifically used to treat chronic myelogenous leukemia (CML). Its main mechanism is to prevent the proliferation of tumor cells by inhibiting the activity of BCR-ABL fusion protein, thereby achieving anti-cancer effects. Especially for those CML patients who have not responded to or developed drug resistance to previous treatments, bosutinib has shown good efficacy. This medication is administered orally, and the dose needs to be adjusted to the patient's specific condition to achieve optimal therapeutic results.

Bosutinib is indicated primarily for adult patients with chronic myelogenous leukemia, especially those whose disease has progressed despite at least first-line treatment. In addition, there are also studies on its application in patient groups where other targeted therapies are ineffective. Clinical studies have shown that bosutinib performs well in the face of these refractory cases and relatively rarely develops drug resistance, making it an important choice in the treatment of CML. Patients may experience some common side effects while taking bosutinib, which are usually manageable, but in some cases, dosage adjustments or temporary discontinuation may be required to ensure patient safety.

Regarding the generic drugs of bosutinib, many pharmaceutical companies currently manufacture related generic drugs in the international market, such as India's Mylan (Mylan). These generic drugs may have been sold in local hospitals or pharmacies. These generic drugs are basically the same as the original drugs in terms of ingredients, efficacy and specifications, but due to different manufacturers, their prices may be more affordable. Common bosutinib generic specifications include 400mg 30 tablets, 500mg 30 tablets and 100mg*120 tablets. Since the production costs of generic drugs are generally lower than those of original drugs, their prices are significantly more affordable, usually priced at more than 1,000 yuan per box (the specific price is affected by exchange rate fluctuations).

Reference materials:https://www.mayoclinic.org/drugs-supplements/bosutinib-oral-route/description/drg-20075783